ASLAN Pharmaceuticals (ASLN) Competitors $0.60 0.00 (0.00%) As of 08/5/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOptions ChainSEC FilingsTrendsBuy This Stock ASLN vs. ORGS, TCRT, DRMA, MTNB, SPRB, ALBT, CMND, VRAX, SNGX, and QLGNShould you be buying ASLAN Pharmaceuticals stock or one of its competitors? The main competitors of ASLAN Pharmaceuticals include Orgenesis (ORGS), Alaunos Therapeutics (TCRT), Dermata Therapeutics (DRMA), Matinas Biopharma (MTNB), Spruce Biosciences (SPRB), Avalon GloboCare (ALBT), Clearmind Medicine (CMND), Virax Biolabs Group (VRAX), Soligenix (SNGX), and Qualigen Therapeutics (QLGN). These companies are all part of the "pharmaceutical products" industry. ASLAN Pharmaceuticals vs. Its Competitors Orgenesis Alaunos Therapeutics Dermata Therapeutics Matinas Biopharma Spruce Biosciences Avalon GloboCare Clearmind Medicine Virax Biolabs Group Soligenix Qualigen Therapeutics ASLAN Pharmaceuticals (NASDAQ:ASLN) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership. Is ASLN or ORGS more profitable? ASLAN Pharmaceuticals has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ASLAN PharmaceuticalsN/A -8,454.87% -121.60% Orgenesis -3,827.81%N/A -130.18% Which has stronger valuation and earnings, ASLN or ORGS? ASLAN Pharmaceuticals has higher revenue and earnings than Orgenesis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioASLAN Pharmaceuticals$12M0.10-$44.22M-$21.92-0.03Orgenesis$662K0.16-$55.36MN/AN/A Which has more risk and volatility, ASLN or ORGS? ASLAN Pharmaceuticals has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, Orgenesis has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Do insiders & institutionals hold more shares of ASLN or ORGS? 58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Comparatively, 5.7% of Orgenesis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer ASLN or ORGS? In the previous week, Orgenesis had 1 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 1 mentions for Orgenesis and 0 mentions for ASLAN Pharmaceuticals. ASLAN Pharmaceuticals' average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score. Company Overall Sentiment ASLAN Pharmaceuticals Neutral Orgenesis Neutral SummaryASLAN Pharmaceuticals beats Orgenesis on 6 of the 10 factors compared between the two stocks. Get ASLAN Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASLN vs. The Competition Export to ExcelMetricASLAN PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.23M$782.21M$5.57B$9.47BDividend YieldN/A4.84%4.31%4.13%P/E Ratio-0.031.3029.3723.99Price / Sales0.1025.47444.1896.63Price / CashN/A19.5635.8458.51Price / Book-0.096.598.085.58Net Income-$44.22M-$4.20M$3.26B$265.35M7 Day PerformanceN/A-3.87%0.45%-0.07%1 Month PerformanceN/A-0.67%4.83%1.76%1 Year PerformanceN/A21.24%30.28%25.39% ASLAN Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330ORGSOrgenesis1.2249 of 5 stars$1.00flatN/AN/A$4.80M$662K0.00150TCRTAlaunos Therapeutics0.4964 of 5 stars$2.85-5.0%N/A+16.4%$4.68M$10K-1.1240Upcoming EarningsGap UpDRMADermata Therapeutics1.7288 of 5 stars$0.72+2.9%$3.00+314.9%-72.5%$4.61MN/A-0.048Positive NewsShort Interest ↑Gap UpMTNBMatinas Biopharma0.5839 of 5 stars$0.89-4.4%N/AN/A$4.55MN/A-0.1830Gap DownSPRBSpruce Biosciences2.4941 of 5 stars$0.11-2.2%$1.75+1,557.2%-99.6%$4.46M$4.91M-0.1120News CoverageNegative NewsUpcoming EarningsGap DownALBTAvalon GloboCare1.1598 of 5 stars$2.28-23.4%N/A-38.8%$4.33M$1.33M-0.115Positive NewsGap DownCMNDClearmind Medicine0.203 of 5 stars$0.99-2.9%N/A-25.0%$4.23MN/A-0.90N/AGap DownVRAXVirax Biolabs Group3.1435 of 5 stars$0.97+1.3%$3.00+210.9%-23.8%$4.19M$10K0.005Gap UpSNGXSoligenix2.0816 of 5 stars$1.28flat$6.00+368.8%-9.3%$4.14M$120K-0.3020Upcoming EarningsGap UpQLGNQualigen TherapeuticsN/A$2.53-9.6%N/A-82.4%$4.14MN/A0.0050 Related Companies and Tools Related Companies ORGS Alternatives TCRT Alternatives DRMA Alternatives MTNB Alternatives SPRB Alternatives ALBT Alternatives CMND Alternatives VRAX Alternatives SNGX Alternatives QLGN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASLN) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ASLAN Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share ASLAN Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ASLN Stock Alerts